|
Genetic polymorphisms associated with clostridium difficile infection in multiple myeloma patients undergoing autologous stem cell transplantation. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Janssen Research & Development |
Consulting or Advisory Role - Janssen Research & Development |
Research Funding - Janssen Research & Development (Inst); Professional Compounding Centers of America (Inst) |
|
|
Patents, Royalties, Other Intellectual Property - Atrium Health |
|
|
No Relationships to Disclose |
|
|
Honoraria - Celgene; Cellectar; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Sanofi; Takeda |
Consulting or Advisory Role - Cellectar; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Sanofi; Takeda |
Speakers' Bureau - Celgene |
|
|
Speakers' Bureau - Amgen; Takeda |
Travel, Accommodations, Expenses - Amgen (I); Takeda (I) |
|
|
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
Consulting or Advisory Role - Janssen Oncology |
|
|
|
Consulting or Advisory Role - Adaptive Biotechnologies; Celgene; GlaxoSmithKline; Janssen; Novartis; Oncopeptides; TeneoBio |
|
|
Consulting or Advisory Role - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen Oncology; Karyopharm Therapeutics; Seagen; Skyline Diagnostics; Takeda |
Speakers' Bureau - Amgen; Celgene; Janssen Oncology; Takeda |
Research Funding - Amgen; Array BioPharma; Bristol-Myers Squibb; Celgene; Janssen Oncology; Pharmacyclics; Sanofi; Seagen |
|
|
No Relationships to Disclose |